JOP20200243A1 - مركبات البلاديينوليد واستخداماتها - Google Patents

مركبات البلاديينوليد واستخداماتها

Info

Publication number
JOP20200243A1
JOP20200243A1 JOP/2020/0243A JOP20200243A JOP20200243A1 JO P20200243 A1 JOP20200243 A1 JO P20200243A1 JO P20200243 A JOP20200243 A JO P20200243A JO P20200243 A1 JOP20200243 A1 JO P20200243A1
Authority
JO
Jordan
Prior art keywords
compounds
cancers
useful
methods
pladienolide
Prior art date
Application number
JOP/2020/0243A
Other languages
English (en)
Inventor
Shelby Ellery
Nicholas C Gearhart
Sonobe Regina Mikie Kanada
Touping Luo
Satoshi Nagao
Marta Nevalainen
Kenzo Arai
Dominic Reynolds
Jason T Lowe
Sudeep Prajapati
Kazunobu Kira
Gregg F Keaney
John Wang
Atsushi Endo
Guo Zhu Zheng
Baudouin Gerard
Xiang Liu
Norio Murai
Ming-Hong Hao
Parcharee Tivitmahaisoon
Yoshihiko Kotake
Lisa A Marcaurelle
Masayuki Miyano
Morgan Welzel O'shea
James Palacino
Andrew Cook
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of JOP20200243A1 publication Critical patent/JOP20200243A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)

Abstract

غير متوفر
JOP/2020/0243A 2018-04-09 2019-04-08 مركبات البلاديينوليد واستخداماتها JOP20200243A1 (ar)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862655021P 2018-04-09 2018-04-09
US201862679653P 2018-06-01 2018-06-01
US201962814843P 2019-03-06 2019-03-06
US201962814838P 2019-03-06 2019-03-06
PCT/US2019/026313 WO2019199667A2 (en) 2018-04-09 2019-04-08 Certain pladienolide compounds and methods of use

Publications (1)

Publication Number Publication Date
JOP20200243A1 true JOP20200243A1 (ar) 2020-09-29

Family

ID=66248768

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2020/0242A JOP20200242A1 (ar) 2018-04-09 2019-04-08 مركبات البلاديينوليد واستخداماتها
JOP/2020/0243A JOP20200243A1 (ar) 2018-04-09 2019-04-08 مركبات البلاديينوليد واستخداماتها

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JOP/2020/0242A JOP20200242A1 (ar) 2018-04-09 2019-04-08 مركبات البلاديينوليد واستخداماتها

Country Status (18)

Country Link
US (1) US11926619B2 (ar)
EP (1) EP3774759A2 (ar)
JP (2) JP7335265B2 (ar)
KR (1) KR20210006907A (ar)
CN (1) CN113166091A (ar)
AU (2) AU2019251096B2 (ar)
BR (1) BR112020020792A2 (ar)
CA (1) CA3096400A1 (ar)
CL (3) CL2020002604A1 (ar)
CO (1) CO2020013834A2 (ar)
IL (2) IL277749B2 (ar)
JO (2) JOP20200242A1 (ar)
MX (2) MX2020010606A (ar)
PE (1) PE20212327A1 (ar)
PH (1) PH12020500666A1 (ar)
SG (1) SG11202009906TA (ar)
TW (1) TW201945351A (ar)
WO (1) WO2019199667A2 (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4240360A1 (en) 2020-11-04 2023-09-13 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same
WO2023131866A1 (en) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same
CN115414351B (zh) * 2022-09-19 2024-05-17 山东大学齐鲁医院 pladienolide B与PD-L1抗体组合在肿瘤免疫治疗领域的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
NZ322175A (en) 1995-11-10 1999-02-25 Elan Corp Plc Peptides which enhance transport across tissues and methods of identifying the same
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
TWI311558B (en) * 2001-02-01 2009-07-01 Mercian Corporatio Novel physiologically active substance
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
JP4459051B2 (ja) 2002-07-31 2010-04-28 メルシャン株式会社 新規生理活性物質
US7256178B2 (en) 2002-07-31 2007-08-14 Eisai Co., Ltd. Physiologically active substances
AU2003285012A1 (en) 2002-10-24 2004-05-13 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
JP4439401B2 (ja) 2002-11-29 2010-03-24 メルシャン株式会社 マクロライド系化合物の製造方法
KR20060110865A (ko) 2003-11-27 2006-10-25 에자이 가부시키가이샤 매크로라이드계 화합물의 수산화에 관여하는 ｄｎａ
DE602005021617D1 (de) * 2004-02-06 2010-07-15 Eisai R&D Man Co Ltd Verfahren zur untersuchung der empfindlichkeit einer krebszelle gegenüber einem antikrebsmittel
CN1977046A (zh) 2004-07-20 2007-06-06 卫材R&D管理有限公司 编码参与普拉地内酯生物合成的多肽的dna
WO2007110705A2 (en) 2005-09-28 2007-10-04 Novimmune Sa Macrolide as inhibitors of mhc class ii
WO2007110704A2 (en) * 2005-09-28 2007-10-04 Novimmune Sa Macrolide compositions as therapeutic agent
CN101282967B (zh) 2005-10-13 2011-01-26 卫材R&D管理有限公司 普拉二烯内酯b和普拉二烯内酯d的全合成
JPWO2008020584A1 (ja) 2006-08-14 2010-01-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定な凍結乾燥製剤
KR20090104002A (ko) 2007-01-29 2009-10-05 에자이 알앤드디 매니지먼트 가부시키가이샤 매크롤라이드계 화합물의 고체, 그의 제조 방법 및 그의 의약 조성물
US20080312317A1 (en) 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives
US20100197919A1 (en) * 2007-07-06 2010-08-05 Toshio Tsuchida Method for producing macrolide compound and production intermediate thereof
WO2013148324A1 (en) * 2012-03-26 2013-10-03 The Regents Of The University Of California Anti-cancer polyketide compounds
KR102193343B1 (ko) 2012-05-15 2020-12-22 브리스톨-마이어스 스큅 컴퍼니 Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
US20140275010A1 (en) * 2013-03-12 2014-09-18 Guo Zhu Zheng Quaternary salts
EP3143016B1 (en) * 2014-05-15 2018-12-12 Eisai R&D Management Co., Ltd. Pladienolide pyridine compounds and methods of use
CN106604933B (zh) 2014-07-11 2021-08-10 文塔纳医疗系统公司 抗pd-l1抗体及其诊断用途
EP3344780B1 (en) * 2015-09-01 2021-06-23 Eisai R&D Management Co., Ltd. Splice variants associated with neomorphic sf3b1 mutants
MX2021001441A (es) * 2015-11-18 2022-05-19 Eisai R&D Man Co Ltd Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso.
KR20210016406A (ko) 2018-06-01 2021-02-15 에자이 알앤드디 매니지먼트 가부시키가이샤 스플라이싱 조정제를 사용하는 방법

Also Published As

Publication number Publication date
TW201945351A (zh) 2019-12-01
MX2022015216A (es) 2023-01-04
PH12020500666A1 (en) 2021-07-26
IL277749B2 (en) 2023-11-01
AU2019251096A1 (en) 2020-11-26
JOP20200242A1 (ar) 2020-09-29
MX2020010606A (es) 2021-01-15
AU2019251096B2 (en) 2023-04-20
CL2022000458A1 (es) 2022-10-21
IL303335A (en) 2023-07-01
SG11202009906TA (en) 2020-11-27
JP2023156456A (ja) 2023-10-24
EP3774759A2 (en) 2021-02-17
WO2019199667A2 (en) 2019-10-17
IL277749A (en) 2020-11-30
BR112020020792A2 (pt) 2021-01-12
JP2021521124A (ja) 2021-08-26
CO2020013834A2 (es) 2020-12-10
PE20212327A1 (es) 2021-12-14
CA3096400A1 (en) 2019-10-17
IL277749B1 (en) 2023-07-01
CN113166091A (zh) 2021-07-23
KR20210006907A (ko) 2021-01-19
US11926619B2 (en) 2024-03-12
AU2023202358A1 (en) 2023-05-18
CL2020002604A1 (es) 2021-01-15
WO2019199667A3 (en) 2019-11-21
JP7335265B2 (ja) 2023-08-29
CL2023002549A1 (es) 2024-01-26
US20210163456A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
NZ729643A (en) Combination therapy for treating cancer
MX2016007351A (es) Terapia de combinacion para tratar cancer.
SG10201902664RA (en) Combination therapy for treating cancer
PH12020500666A1 (en) Pladienolide compounds and their use
PH12016502249A1 (en) Pladienolide pyridine compounds and methods of use
CR20220207A (es) Compuestos terapéuticos y métodos de uso
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
ZA201808562B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
WO2015035410A8 (en) Cancer therapy
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
EA202191415A1 (ru) Комбинированная терапия, включающая ингибитор krasg12c и одно или несколько дополнительных фармацевтически активных средств, для лечения видов рака
EA202091908A3 (ru) Комбинированная терапия для лечения онкологического заболевания